Management of chronic thromboembolic pulmonary hypertension (CTEPH) includes multimodal therapy that depends on expert ...

Antiphospholipid antibody syndrome (APS) may lead to pulmonary hypertension, a lethal complication of chronic pulmonary thromboembolism. There are few viable treatment options for pulmonary ...

Recurrent pulmonary embolism as a cause of chronic heart disease was probably first recognized by Ljungdahl 8 in 1928. Brenner, 9 in his systematic studies of the pulmonary vasculature in 1935 ...

This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello, everyone, and welcome to this Medscape InDiscussion podcast. Today we're talking about chronic thromboembolic pulmonary ...

Chronic thromboembolic pulmonary hypertension (CTEPH) is high blood pressure in the arteries in your lungs. You can get it after you've had a pulmonary embolism (PE) -- a blood clot in your lung ...

In the patients with pulmonary thromboembolism the major arteriographic abnormalities were complete or incomplete obstruction of various pulmonary arterial branches (Fig. 3 B, 4 B and 5 B ...

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonary hypertension. This is caused by a pro-inflammatory state secondary to unresolved clot that results in pulmonary vessel ...

The phosphodiesterase-5 (PDE-5) inhibitor, sildenafil, has been reported to produce sustained pulmonary vasodilatation in patients with pulmonary hypertension (PH). Recently, vardenafil, a more ...

Often promoted as a healthier alternative to smoking, vaping increases the chances of developing chronic pulmonary diseases like emphysema, asthma and bronchitis by 30%, the report said.

During the 3-month follow-up, 5 of 670 patients who were discharged without anticoagulation were diagnosed with PE (0.7%, 95% CI 0.3% to 1.7%), and 3 of them died.